RA Capital Management 13F holdings, Q2 2013
Holdings as of June 30, 2013 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 25 US equity positions worth $616.0m in its Q2 2013 13F filing. The largest position was ACAD at 19.2% of the reported book, followed by ACHILLION PHARMACEUTICALS IN and KERYX BIOPHARMACEUTICALS INC. Against the Q1 2013 filing, it opened 13 new positions, added to 4 and reduced 5 among the top 25 holdings.
What did RA Capital Management own in Q2 2013? Top 25 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2013 |
|---|---|---|---|---|---|---|---|
| 1 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 19.2% | $118.5m | 6,529,810 | -40% | reduced |
| 2 | ACHILLION PHARMACEUTICALS IN | 9.9% | $61.0m | 7,455,202 | – | new | |
| 3 | KERYX BIOPHARMACEUTICALS INC | 6.9% | $42.3m | 5,659,285 | 0% | held | |
| 4 | SGMOQ SANGAMO BIOSCIENCES INC | Healthcare | 6.8% | $41.9m | 5,368,094 | -8% | reduced |
| 5 | DYAX CORP | 6.1% | $37.7m | 10,908,379 | 28% | added | |
| 6 | NEWLINK GENETICS CORP | 5.9% | $36.3m | 1,840,294 | 16% | added | |
| 7 | NVAX NOVAVAX INC | Healthcare | 5.7% | $35.2m | 17,170,801 | 16% | added |
| 8 | TXMD THERAPEUTICSMD INC | 5.5% | $34.1m | 11,262,608 | – | new | |
| 9 | INSM INSMED INC | Healthcare | 4.7% | $29.1m | 2,433,319 | – | new |
| 10 | DERMA SCIENCES INC | 4.3% | $26.6m | 1,994,876 | 27% | added | |
| 11 | SUNESIS PHARMACEUTICALS INC | 4.0% | $24.5m | 4,716,296 | -3% | reduced | |
| 12 | XOMA CORP DEL | 3.9% | $24.3m | 6,698,558 | 0% | held | |
| 13 | HYPERION THERAPEUTICS INC | 3.2% | $19.9m | 902,858 | -15% | reduced | |
| 14 | RECEPTOS INC | 3.1% | $19.4m | 975,000 | – | new | |
| 15 | OMER OMEROS CORP | 2.4% | $14.9m | 2,953,004 | – | new | |
| 16 | ONCOGENEX PHARMACEUTICALS IN | 1.4% | $8.5m | 863,332 | – | new | |
| 17 | ENTA ENANTA PHARMACEUTICALS INC | Healthcare | 1.3% | $7.7m | 436,145 | – | new |
| 18 | ENZB ENZO BIOCHEM INC | 1.1% | $7.0m | 3,348,029 | – | new | |
| 19 | DYNAVAX TECHNOLOGIES CORP | 1.1% | $6.6m | 6,000,000 | – | new | |
| 20 | PROTHENA CORP PLC | 1.0% | $6.4m | 497,807 | – | new | |
| 21 | ARROWHEAD RESH CORP | 1.0% | $6.2m | 3,114,755 | – | new | |
| 22 | EPIZYME INC | 0.7% | $4.2m | 151,000 | – | new | |
| 23 | SENOMYX INC | 0.3% | $2.1m | 975,610 | -35% | reduced | |
| 24 | TRANZYME INC | 0.2% | $1.3m | 2,700,000 | – | new | |
| 25 | SAVIENT PHARMACEUTICALS INC | 0.0% | $228.0k | 1,000,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.